Pluri Inc. (PLUR) Fair Value 2026

PLUR · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.3 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (38/100)

Quick Summary — As of 2026-10-07, Pluri Inc. (PLUR) trades at $0.99. QOC: 6.3/10. Value Trap Risk: 38/100 (LOW). 1/13 models active.

Key Facts

Ticker
PLUR
Price
$0.99
Quality Score
6.3/10
Value Trap Risk
38/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +25.4% upside with 32% confidence
Risk: Limited model coverage (1/13) may reduce confidence

What Fair Value Does Each Model Give PLUR?

1 Intrinsic Value Models vs. Current Price ($0.99)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $1.24 +25.4%

All Models Active

All 1 models are displayed above.

What Is Pluri Inc. (PLUR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Pluri Inc. is potentially undervalued at its current price of $0.99. Based on our 13-model framework, Pluri Inc.'s intrinsic value is estimated at a median fair value of $1.24 — representing +25.4% implied upside — with 1 out of 1 active models confirming this thesis.

What Do the Models Say About PLUR?

1 of 13 models are currently active for PLUR. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does PLUR Rank in Biotechnology?

Among 622 Biotechnology stocks, PLUR ranks #122 by Quality of Company score. CirclFi's QOC score of 6.3/10 evaluates 32 fundamental signals. A score of 6.3 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Pluri Inc. competes in an environment where pipeline depth and stage distribution often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is PLUR a Value Trap?

CirclFi's Value Trap algorithm assigns PLUR a score of 38/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Pluri Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Pluri Inc. is rated at 6.3/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PLUR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PLUR's 1 active models, average confidence is 32%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Pluri Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

NTLAIntellia Therapeutics, Inc.QOC 6.3CDXSCodexis, Inc.QOC 6.2EVMNEvommune, Inc.QOC 6.3ATHEAlterity Therapeutics LimitedQOC 6.2PHATPhathom Pharmaceuticals, Inc.QOC 6.3CRDFCardiff Oncology, Inc.QOC 6.2GDTCCytoMed Therapeutics LimitedQOC 5.1AVBPArriVent BioPharma, Inc.QOC 4.5BLSMBlossomHill Therapeutics, Inc.QOC 3.2EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: NTLA · CDXS · EVMN · ATHE · PHAT · CRDF · GDTC · AVBP · BLSM · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to PLUR?

6 companies across all industries closest to PLUR’s Quality of Company score of 6.3/10.

BDSXBiodesix, Inc.QOC 6.3CRDLCardiol Therapeutics Inc.QOC 6.3TXMDTherapeuticsMD, Inc.QOC 6.3EVGOEVgo, Inc.QOC 6.3DQWSDSwiss, Inc.QOC 6.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: BDSX · CRDL · TXMD · EVGO · DQWS · NVDA

Where Does PLUR Sit in CirclFi's Biotechnology Rankings?

PLUR is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Pluri Inc.’s Valuation?

What is Pluri Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Pluri Inc. (PLUR). The Quality of Company score is 6.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PLUR overvalued or undervalued right now?

At $0.99, 1 of 1 active models suggest PLUR may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Pluri Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.3 mean for PLUR?

Pluri Inc.'s QOC of 6.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on PLUR?

CirclFi analyzes PLUR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is PLUR a value trap in 2026?

Pluri Inc.'s Value Trap score is 38/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Pluri Inc. (PLUR) a Quality of Company score of 6.3/10 across 32 fundamental signals as of 2026-10-07.” Source: circlfi.com/stock/PLUR/ · Methodology
Primary sources for this PLUR valuation
  • Financial statements: Pluri Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001158780) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PLUR as of ; valuations recomputed .